Michael Burry's top dividend stocks (September 2025) include Unitedhealth Group Inc (UNH), a leading diversified health and well-being company offering a broad range of healthcare products and services.

Michael Burry is a renowned investor who heads Scion Asset Management, his personal hedge fund. His investment strategy often involves deep value research and identifying mispriced assets, making him a closely watched figure in the financial world. Scion Asset Management focuses on fundamental analysis to uncover compelling investment opportunities.

Unitedhealth Group Inc (UNH)

Unitedhealth Group is a global leader in healthcare, providing a wide array of health insurance plans, healthcare services, and technology-driven solutions. Their Optum segment offers pharmacy care services, data analytics, and care delivery. This position currently represents a significant $6.2 million in Michael Burry's portfolio. The company offers investors a dividend yield of approximately 2.75%, distributing a trailing twelve-month dividend rate of $8.51 per share. Analysts generally place a price target for UNH around $352.4, while its discounted cash flow value is estimated at $1.09K.
Here's an overview of Michael Burry's trades in Unitedhealth Group Inc:

Estee Lauder Cos., Inc. (EL)

Estee Lauder is a global powerhouse in prestige beauty, manufacturing and marketing skincare, makeup, fragrance, and hair care products. Their extensive portfolio includes many well-known brands sold in over 150 countries and territories. Michael Burry's portfolio holds a current value of $13.76 million in Estee Lauder. Shareholders enjoy a dividend yield of roughly 1.86%, with the trailing twelve-month dividend rate standing at $1.71. The stock carries an analyst price target of $85.0, alongside an estimated discounted cash flow value of $34.09.
Here's an overview of Michael Burry's trades in Estee Lauder Cos., Inc.:

Bruker Corp (BRKR)

Bruker Corporation is a leading manufacturer of high-performance scientific instruments and analytical solutions. They specialize in systems for molecular and materials research, as well as industrial and applied analysis, serving diverse markets including life science, pharma, and material science. With a current portfolio value of $8.5 million, Bruker Corp offers a dividend yield of approximately 0.59%. Its trailing twelve-month dividend rate is $0.2 per share. The analyst price target for BRKR is noted at $47.67, with a discounted cash flow value around $74.11.
Here's an overview of Michael Burry's trades in Bruker Corp:

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals is a leading biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Their innovative approach focuses on various therapeutic areas, including eye diseases, allergic and inflammatory diseases, cancer, and cardiovascular disease. The current value of this position in Michael Burry's portfolio is $8.71 million. Regeneron provides a dividend yield of about 0.45%, reflecting a trailing twelve-month dividend rate of $3.52 per share. Analysts have set a price target for REGN at $660.5, and its discounted cash flow value is estimated to be $2.02K.
Here's an overview of Michael Burry's trades in Regeneron Pharmaceuticals, Inc.: